Recurrent Sebaceous Gland Carcinoma of the Eyelid with Metastasis to the Parotid Gland and the Regional Lymph Nodes: Case Report and Review of the Literature

Vafeiadou Margarita1*, Alexoudi Vaia-Aikaterini2, Kilmpasani Maria2, Karafoulidou Ioanna2 and Antoniades Konstantinos1

1Department of Oral and Maxillofacial Surgery, Aristotle University of Thessaloniki, Greece
2Department of Pathology, General Hospital of Thessaloniki “G. Papanicolaou”, Thessaloniki, Greece

Abstract
Sebaceous cell carcinoma is a rare cutaneous aggressive tumor arising from the sebaceous glands. Its almost exclusive site of occurrence is the eyelid but it has also been reported primarily in other sites, such as the parotid region. It is one of the most dangerous tumors, due to masquerading as inflammatory conditions, such as blepharoconjunctivitis, superior limbic keratoconjunctivitis or chalazion. It may also be misdiagnosed as other malignancies, while the incidence of metastasis is high—about 41%.

In our article we report a rare case of a recurrent sebaceous gland carcinoma of the eyelid with metastasis to the parotid gland and the regional lymph nodes.

In the review of the literature, diagnosis, treatment and the prognosis of this rare entity are described.

Introduction
Sebaceous cell carcinoma is a cutaneous aggressive tumor arising from the sebaceous glands. It is considered as the third most common eyelid malignancy after basal and squamous cell carcinomas. Its almost exclusive site of occurrence is the eyelid but it has also been reported primarily in other sites, such as the parotid region. Among western population it accounts for < 1-5.5%, while in Asians it can be observed at about 31-39% [1-7].

Sebaceous cells are predominantly present in meibomian glands of the tarsal plate, sebaceous glands of ocular adnexa (gland of Zeis), sebaceous glands embedded in caruncle, brow and associated hair follicles of lid skin. The most common site of occurrence is the upper eyelid.

It has been reported as the great masquerader, due to its resemblance to other benign or malignant lesions. In the differential diagnosis chalazion, blepharitis, conjunctivitis, basal cell carcinoma, squamous cell carcinoma, leukoplakia, ocular pemphigoid and carcinoma in-situ must be concerned [1,5,8-10].

We report a case of a parotid metastasis originating from a carcinoma of the upper eyelid, diagnosed as sebaceous cell carcinoma. Diagnosis and treatment of this entity are described.
that had been dissected, were positive for metastasis of the above carcinoma.

The patient underwent further radiotherapy and is under regular follow-up in the external unit of our clinic (Figure 4a, Figure 4b). There is no recurrence so far.

Discussion

Sebaceous carcinoma, sebaceous gland carcinoma (SGC), sebaceous cell carcinoma and meibomian gland carcinoma are all terms used in the literature to malignant neoplasm of...
sebaceous origin. Sebaceous carcinoma is traditionally classified into two groups: Tumor arising from the ocular adnexa in the periocular area and those arising in the extraocular sites, which commonly involve the head and neck region, the parotid and submandibular glands, the external auditory canal, the trunk and laryngeal or pharyngeal cavities. It is considered to be the third most common eyelid malignancy – after basal cell and squamous cell carcinoma - representing 1-5.5% of all eyelid tumors. However, it is one of the most dangerous tumors, due to masquerading as inflammatory conditions, such as blepharoconjunctivitis, superior limbic keratoconjunctivitis or chalazion. It may also be misdiagnosed as other malignancies. The result is delayed diagnosis or wrong treatment [1,3,5,7-11].

In addition to its variable clinical appearance, a variable histologic appearance may also occur. As a result, delayed diagnosis or misdiagnosis following biopsy is not uncommon. Eyelid sebaceous gland carcinoma has a characteristic intraepithelial growth pattern, resulting from a pagetoid spread or a full-thickness replacement of the surface epithelium. The tumor may demonstrate well, moderately or poorly differentiated areas. The histologic examination may reveal a papillary or lobular growth pattern of neoplastic cells with evident sebaceous differentiation, or highly atypical neoplastic cells with prominent nuclear pleomorphism. Areas of necrosis and fibrosis are commonly found. The spread of the tumor in the form of infiltrating lobules, nests and cords is characteristic, perineural invasion is observed in about 20% of tumors, whereas vascular invasion is extremely infrequent [2,4,12-14].

The treatment of SGCs is adequate surgical excision with wide surgical margins and fresh frozen section controls. When the tumor diffuses the eyelid, orbital exenteration is required. Radical or selective neck dissection should be performed, to evaluate lymph node metastasis. Adjunctive radiotherapy or chemotherapy are necessary, depending on the stage of the tumor at the time of presentation, or when the surgical margins are diffused [1,3,6,8,9,11,13,15,16].

In our case, the patient presented with a parotid gland metastasis. Given her history of a surgical excision of a squamous cell carcinoma of the lower eyelid 4 years ago, the parotid gland tumor was thought to be a metastatic SCC. Unfortunately, we had no chance to histologically reexamine the
Well-differentiated tumors have a better prognostic outcome in contrast to the poorly differentiated. Confirmation of pagetoid spread is another bad prognostic factor. Other adverse prognostic features include the involvement of both upper and lower eyelid, tumor size more than 10 mm, orbital extension and infiltration of blood vessels and/or lymphatics [1,3,5-7,10].

Metastasis can occur by continuous growth, lymphatic spread or hematogenous spread. The most common sites of continuous growth is the orbit, the periaucular area and the parotid gland, as well as the regional lymph nodes of level I and II. More rare is distant metastasis to the lung, pleura, liver, brain, pericardium, lips, ethmoid sinus and skull. The overall mortality rate is 5 - 10%, while in cases of metastasis the rate may go up to 25% and up to 41% in cases where the duration of symptoms lasts more than six months [1,3,8,9,11-14].

Conflict of Interest Declaration

The authors declare no conflicts of interest regarding the publication of this paper.

References

1. Rizvi SA, Alam S, Akhtar K (2018) Eyelid sebaceous gland carcinoma: Varied presentations and reconstruction outcome. Oman J Ophthalmol 11: 21-27.
2. Kanwalpreet Kaur, Karuna Gupta, Kalpana Mangal, et al. (2017) Histopathological Analysis of Skin Adnexal Tumors: A Three Year Study of 110 Cases at A Tertiary Care Center. Indian J Dermatol 62: 400-406.
3. El Amin Marnouche, Abdelhak Maghous, Noureddine Benjaafar, et al. (2016) Sebaceous carcinoma of the parotid gland: a case report and review of the literature. J Med Case Rep 10: 174.
4. Prem Chand, Ashok Kumar, Lakshay Singla, et al. (2016) Unusual Presentation of Ulcerative Postauricular Swelling as Sebaceous Cell Carcinoma. Niger J Surg 22: 127-129.
5. Upender K Wali, Abdullah Al-Mujaini (2010) Sebaceous gland carcinoma of the eyelid. Oman J Ophthalmol 3: 117-121.
6. Evan Silverstein, Marcus Marcet (2019) Sebaceous carcinoma. American Academy of Ophthalmology.
7. Glassman M, Roy H (2017) Sebaceous Gland Carcinoma. Medscape.
8. Shields JA, Demirci H, Marr BP, et al. (2004) Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthal-mology 111: 2151-2157.
9. Waseem M, Humayun S (2010) Ayaz B Sebaceous Carcinoma of Upper Eyelid Journal of the College of Physicians and Surgeons Pakistan 20: 487-489.
10. Fan B, Liu JJ, Li GY, et al. (2017) Case report repairing orbital skin defects using composite flaps after giant eyelid-derived tumor excision and orbital exenteration. Medicine Baltimore 96: e8978.
11. Song A, Carter KD, Syed NA, et al. (2008) Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthalmic Plast Reconstr Surg 24: 194-200.
12. Hashimoto K, Yasumatsu R, Toh S, et al. (2016) Patterns of lymphatic spread and the management of eyelid carcinomas. Auris Nasus Larynx 43: 666-671.

Figure 4: a,b) The patient postoperatively, after the complication of the radiotherapy.
13. Soares CD, Morais TML, Carlos R, et al. (2018) Sebaceous adeno-carcinomas of the major salivary glands: a clinicopathological analysis of 10 cases. Histopathology 73: 585-592.

14. SV Deo, Nootan Kumar Shukla, Mandep Singh, et al. (2012) Locally Advanced Sebaceous Cell Carcinoma (T3) of Eyelid: Incidence and Pattern of Nodal Metastases and Combined Modality Management Approach. Orbit 31: 150-154.

15. Lally SA, Rao R, Sheilds JA, et al. (2018) Comparison of posterior lamellar resection versus lumpectomy for initial management of localized tarsal conjunctival sebaceous carcinoma in 54 cases. Indian J Ophthalmol 66: 1295-1300.

16. Sandosh G Honavar (2018) Sebaceous gland carcinoma: Can we do better? Indian J Ophthalmol 66: 1235-1237.